Synopsys (SNPS) Valuation Spotlight Following Class Action Lawsuit Over Design IP Disclosures and Performance

Synopsys (SNPS) is facing a class action lawsuit that centers on allegations about the company’s handling of disclosures related to its Design IP business. Investors are reacting because the legal action highlights missed forecasts and a significant drop in segment performance.

See our latest analysis for Synopsys.

Synopsys has had a turbulent year, with its recent legal troubles and disappointing Design IP segment results adding to investor anxiety. The share price return year-to-date stands at -5.99%, reflecting a clear loss of momentum. Its one-year total shareholder return is down 12.46%. Despite those setbacks, Synopsys has still delivered a strong 64.09% total shareholder return over three years, which underscores its longer-term growth story amidst the recent volatility and news headlines.

If you are keeping an eye on how industry leaders are adapting to today's challenges, it could be the ideal moment to broaden your search and discover See the full list for free.

The question now is whether Synopsys shares reflect all this uncertainty and risk, or if investors are overlooking future profit potential. This could leave room for a genuine buying opportunity in the current market.

Most Popular Narrative: 18% Undervalued

With Synopsys last closing at $453.82 and the most widely followed narrative implying a fair value of $556.40, the stage is set for debate around the future performance fueling this valuation relative to today’s price.

The acquisition and integration of Ansys positions Synopsys as the global leader in engineering solutions from silicon to systems. This move dramatically expands its addressable market into sectors like automotive, industrial, and aerospace. It is expected to support long-term top-line growth as more sophisticated and complex products, especially AI-powered and smart devices, require robust simulation, analysis, and EDA tools.

Read the complete narrative.

Want to know the growth blueprint behind this high valuation? The key element of this narrative is aggressive projections for future revenue, profit margins, and an earnings multiple typically reserved for top-tier tech. Which bold financial levers are driving this price target? Dive into the full story to uncover the big assumptions that fuel this discounted value.

Result: Fair Value of $556.40 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent China-related headwinds and underperformance in the IP segment could challenge Synopsys’s valuation story if these risks do not subside soon.

Find out about the key risks to this Synopsys narrative.

Another View: High Valuation Risk Based on Multiples

Looking from a different perspective, Synopsys currently trades at a price-to-earnings ratio of 72.3x. This is noticeably higher than both the US Software industry average of 34.7x and its peer average of 67.1x. In fact, it is well above the fair ratio level of 45.4x that the market could eventually move toward.

This kind of premium pricing suggests the market is assuming a lot of growth ahead, making the shares vulnerable to disappointment if those expectations are not met. Is the stock exposed to a sudden reset if sentiment shifts?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Synopsys Narrative

If you see things differently or want to dig into the numbers on your own terms, you can build a custom narrative in just a few minutes. So why not Do it your way

A great starting point for your Synopsys research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Smart investors never stop searching for their next big win. Give yourself the edge by using the Simply Wall Street Screener to uncover strategies others might miss.

• Spot tomorrow’s standouts by reviewing these 832 undervalued stocks based on cash flows, which are backed by real cash flow strength and value-driven fundamentals.
• Tap into emerging trends as you follow these 33 healthcare AI stocks, which tackles some of the world's biggest challenges with AI-powered medical breakthroughs and diagnostics.
• Catch the momentum of transformation and gain broad exposure with these 81 cryptocurrency and blockchain stocks, a leader in blockchain and digital asset innovation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com